You need to login...
If you are not registered...
| Subscribe to Krixos Health: | |
|
or call us on: +43 (0)1 27 63 015 or email: subscribe@krixos.com |
|
Most viewed
- 1. Evidence-Based Clinical Protocols to Monitor Efficacy of [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data.
- 2. Sexual activity in men undergoing ADT for localized prostate cancer: a narrative literature review.
- 3. Follow-up of hereditary endometrial carcinoma caused by MLH3 gene mutation: a case report
- 4. ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting
- 5. Accent Therapeutics Presents Data Supporting Therapeutic Potential of First-in-Class DHX9 Inhibitor, ATX-559, and Novel KIF18A Inhibitor, ATX-295, at the AACR Annual Meeting 2025
- 6. Association of aggregate index of systemic inflammation with increased all-cause and cardiovascular mortality in female cancer patients
- 7. LSM2 drives glioma progression through alternative splicing dysregulation: a multi-omics approach to identify a potential therapeutic target
- 8. Human medicines European public assessment report (EPAR): Dazublys, trastuzumab, Status: Opinion
- 9. Novartis posts better-than-expected sales driven by medicine demand
- 10. Why brain metastases of breast cancer resist a promising candidate therapy
Last updated at 13:19 GMT
Hot News Makers
Health/Pharma Companies
-
21351.23
-
14548.03
-
13445.07
-
11429.40
-
11329.51
-
9263.04
-
7989.04
-
6459.56
-
4590.50
-
4462.18
Drugs, Treatments, Trials
-
23690.75
-
14305.09
-
12270.04
-
7736.72
-
4894.21
-
4333.67
-
3529.23
-
3504.66
-
3444.64
-
2572.69
Last updated at 13:10 GMT
